Zymeworks
Zymeworks is a biotechnology company focused on optimizing protein-based therapeutics, particularly for cancer treatment. It uses proprietary computational methods to engineer differentiated product candidates, with its lead asset zanidatamab in multiple clinical trials targeting HER2-expressing solid tumors.
Top Regions
Top Stages
1 past transactions
Kairos Therapeutics
Acquisition in 2016
Kairos Therapeutics, established as a biopharmaceutical company, specializes in developing innovative cancer treatments using its proprietary next-generation antibody-drug conjugate (ADC) platform. This platform facilitates the creation of therapeutics targeting various types of cancer by combining monoclonal antibodies with potent cytotoxic agents.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.